Home / Specialties / Cardiology (page 5)

Cardiology

Cardiovascular Health and Diabetes: Diabetes is an inflammatory, cardiometabolic disease. It elevates nearly every cardiovascular risk factor, and most diabetes patients will die from cardiovascular disease. However, insights from new clinical research along with patient education provide new edges to improve cardiovascular outcomes in your diabetes patients.

Using GLP‑1s in HFpEF and Diabetes: Bringing New Evidence to Breathless Patients

Illustration of a human heart with preserved ejection fraction surrounded by GLP‑1 therapy tools and diabetes monitoring devices.

In clinical practice, patients with both type 2 diabetes and heart failure with preserved ejection fraction (HFpEF) often present with overlapping symptoms and complex care needs. The evolving landscape of cardiometabolic treatment has brought new attention to GLP‑1 HFpEF diabetes management, especially as recent evidence suggests that glucagon-like peptide‑1 receptor …

Read More »

Cardiometabolic Risk in Women With Diabetes: Screening and Care Strategies

A woman with diabetes consults a female doctor about cardiometabolic health, surrounded by medical icons including heart, cholesterol, and blood pressure.

Did you know that women with diabetes have a significantly higher risk of heart disease compared to men with diabetes? While many of the standard care guidelines apply to all patients, women often face additional, underrecognized threats to their heart and metabolic health. Understanding how sex-specific factors—such as hormonal changes, …

Read More »

Cardiorenal-Metabolic Disease in Focus: Applying the CKM Framework in Diabetes Practice

Composite image showing cardiovascular, kidney, and metabolic health tools including glucometer, medications, and a CKM concept diagram on a doctor’s desk.

The CKM framework in diabetes care—focusing on cardiovascular, kidney, and metabolic health—is more than a trend. It’s a clinical necessity. The ADA’s 2025 Standards of Care urge clinicians to manage these overlapping risks together, not separately. Why? Because patients with diabetes deserve outcomes that go beyond just A1C. This article …

Read More »

Beyond GLP‑1s: Are We Overlooking the Role of SGLT2 Inhibitors and Metformin?

Assorted diabetes medications including metformin and SGLT2 inhibitors arranged on a wooden surface beside a white pill bottle.

Clinicians and care teams are increasingly focused on GLP‑1 receptor agonists, but SGLT2 inhibitors and metformin in diabetes management remain foundational in achieving comprehensive, evidence‑based outcomes. While GLP‑1 therapies generate headlines for weight loss and glucose control, 2025 guidelines still strongly emphasize the cardioprotective and renoprotective benefits of SGLT2 inhibitors …

Read More »

When Diabetes Isn’t the Main Problem: Managing Comorbidities Without Losing Focus

Medical stethoscope, glucose meter, and a clipboard showing icons for heart, kidneys, and brain, symbolizing comorbidities in type 2 diabetes management.

Living with type 2 diabetes often means managing more than just blood glucose. For many patients, conditions like cardiovascular disease, chronic kidney disease, or depression take center stage in their care plan. When diabetes isn’t the main problem, how do you keep glucose control on track without compromising treatment for …

Read More »

Insulin Omission for Weight Loss in a Female Adolescent Treated With Advanced Hybrid Closed-Loop System

In a recent article published in the journal Diabetes Care, researchers from Israel reported on a case of a female adolescent with type 1 diabetes who was intentionally omitting insulin in an attempt to lose weight. The adolescent was treated with an advanced hybrid closed-loop system (AHCL), which is a …

Read More »

Blood Pressure Target in Type 2 Diabetes Mellitus

Abstract  The prevalence of diabetes mellitus continues to increase worldwide, and it is a well-established cardiovascular risk factor. Hypertension is also an important cardiovascular risk factor to be controlled and is common among patients with diabetes mellitus. Optimal blood pressure (BP) goals have been the subject of great debate in …

Read More »

Bromocriptine-QR Therapy and its Impact on the Pro-inflammatory State of Type 2 Diabetes Subjects in Relation to CVD

Sponsored Content  Bromocriptine-QR (Cycloset) “is a sympatholytic dopamine D2 agonist for the treatment of type 2 diabetes that has demonstrated rapid (within 1 year) substantial reductions in adverse cardiovascular events in this population by as yet incompletely delineated mechanisms.” This study investigated the impact of Cycloset on the pro-inflammatory state …

Read More »